← FDA WARNING LETTERS
FDA WARNING LETTER8 September 2026
Stephen J. Fallon, Ph.D. — FDA Warning Letter
Bioresearch Monitoring Program/Institutional Review Board (IRB)
What this record is not
Warning-letter details are published by the U.S. FDA; SPEQ surfaces them for reference and is not affiliated with or endorsed by the FDA. The authoritative text is on fda.gov.
Company
Stephen J. Fallon, Ph.D.
Letter date
8 September 2026
Issuing office
Center for Biologics Evaluation and Research (CBER)
What this signals · SPEQ interpretation
SPEQ reads this warning letter’s stated subject as touching clinical trial conduct. That is a keyword reading of the published subject, not an official classification — the requirements and playbooks below are where a team would look to prevent or close it.
Requirements behind it
Decode the practice
DisciplinesGCP
READ THE FULL LETTER
The complete warning letter, including every cited observation, is published by the FDA. SPEQ surfaces and indexes it for reference — the authoritative text lives on fda.gov.
View on fda.gov →